<DOC>
	<DOC>NCT00658333</DOC>
	<brief_summary>To determine if conversion to enteric coated MPA allows an escalated dose of mycophenolic acid (MPA) to be tolerated in patients experiencing gastrointestinal (GI) symptoms</brief_summary>
	<brief_title>A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria: Recipients of first or second cadaveric, living unrelated or living related kidney transplant. Patients on a reduced daily dose (500mg to 1500mg) of MMF with existing but tolerable and controlled gastrointestinal symptoms. Recipients who are at least 4 weeks post renal transplantation with stable renal function. Exclusion criteria: Multi organ transplant or previous transplant with organ other than kidney History of GI disorder prior to transplant Evidence of GI disorder induced by infection, underlying medical condition, or con med other than MMF Modification of GI med or MMF dose within one week Evidence of graft rejection, treatment of acute rejection, unstable renal function within 1 week of (baseline) visit Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Renal transplant recipients</keyword>
	<keyword>Gastrointestinal symptoms associated with MMF therapy</keyword>
</DOC>